title: Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.
abstract: Vascular endothelial growth factor (VEGF), basic-fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and angiogenin are important angiogenic factors. In 65 patients with non-Hodgkin's lymphoma (NHL), pre-treatment VEGF, bFGF, and HGF levels were significantly elevated compared to normal individuals, while angiogenin levels were significantly subnormal. In 37 patients with Hodgkin's disease, pre-treatment levels of VEGF and HGF were significantly elevated, bFGF levels were normal, and angiogenin levels were significantly subnormal. In patients with NHL, post-therapy levels of angiogenin were independently predictive of survival. Both pre-therapy and post-therapy VEGF levels were independently predictive of survival in patients with HD.
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, The University of Texas, PO Box 428, 1515 Holcombe Boulevard, Houston, TX 77030, USA. fgiles@mdanderson.org
authors.forename: Francis J
authors.initials: FJ
authors.lastname: Giles
authors.forename: Julie M
authors.initials: JM
authors.lastname: Vose
authors.forename: Kim-Anh
authors.initials: KA
authors.lastname: Do
authors.forename: Marcella M
authors.initials: MM
authors.lastname: Johnson
authors.forename: Taghi
authors.initials: T
authors.lastname: Manshouri
authors.forename: Gregory
authors.initials: G
authors.lastname: Bociek
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Bierman
authors.forename: Susan M
authors.initials: SM
authors.lastname: O'Brien
authors.forename: Hagop M
authors.initials: HM
authors.lastname: Kantarjian
authors.forename: James O
authors.initials: JO
authors.lastname: Armitage
authors.forename: Maher
authors.initials: M
authors.lastname: Albitar
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood; D017228:Hepatocyte Growth Factor / Q000097:blood; D006689:Hodgkin Disease / Q000097:blood* / Q000473:pathology / Q000628:therapy; D006801:Humans; D008224:Lymphoma, Follicular / Q000097:blood / Q000473:pathology / Q000628:therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000473:pathology / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating / Q000378:metabolism* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000097:blood*; D011237:Predictive Value of Tests; D012259:Ribonuclease, Pancreatic / Q000097:blood; D015996:Survival Rate; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; D017228:Hepatocyte Growth Factor; C046366:angiogenin; D012259:Ribonuclease, Pancreatic